NEW YORK (GenomeWeb News) - Gene Logic said today that it has signed a drug-repositioning agreement with Abbott that covers multiple clinical drug candidates that have passed Phase I human clinical trials.
 
Gene Logic said it stands to receive milestone payments for each new drug candidate that Abbott reenters into clinical development, as well as royalties for drug candidates that make it to market.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.